|
CN105658672A
(zh)
|
2013-08-22 |
2016-06-08 |
阿塞勒隆制药公司 |
TGF-β受体II型变体及其用途
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
MX381141B
(es)
|
2014-02-10 |
2025-03-12 |
Merck Patent Gmbh |
INHIBICIÓN DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
|
CN116327915A
(zh)
*
|
2015-04-03 |
2023-06-27 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
WO2017024171A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
CA2999756A1
(en)
*
|
2015-09-24 |
2017-03-30 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for reducing metastases
|
|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
WO2017165681A1
(en)
|
2016-03-24 |
2017-09-28 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
JP7359547B2
(ja)
*
|
2016-05-17 |
2023-10-11 |
ジェネンテック， インコーポレイテッド |
免疫療法における診断及び使用のための間質遺伝子シグネチャー
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
IL264730B2
(en)
*
|
2016-08-12 |
2024-09-01 |
Merck Patent Gmbh |
PHARMACEUTICAL COMPOSITION COMPRISING TGFbetaRII AND ANOTHER ANTI-CANCER AGENT
|
|
KR102617453B1
(ko)
|
2016-09-19 |
2023-12-26 |
현대모비스 주식회사 |
보조 표지판 인식 장치 및 그 방법
|
|
JP7421338B2
(ja)
|
2016-09-27 |
2024-01-24 |
エピセントアールエックス，インコーポレイテッド |
免疫調節融合タンパク質
|
|
TW202436356A
(zh)
|
2016-10-11 |
2024-09-16 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
US11013802B2
(en)
|
2016-12-07 |
2021-05-25 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
JP2020514290A
(ja)
*
|
2017-01-07 |
2020-05-21 |
メルク パテント ゲーエムベーハー |
標的ｔｇｆ−β阻害のための投薬計画及び投薬形態
|
|
CA3049652A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
GB201700567D0
(en)
*
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
|
EP3568412A2
(en)
|
2017-01-13 |
2019-11-20 |
Agenus Inc. |
T cell receptors that bind to ny-eso-1 and methods of use thereof
|
|
JP7231553B2
(ja)
|
2017-03-02 |
2023-03-01 |
ナショナル リサーチ カウンシル オブ カナダ |
Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用
|
|
MX2019011657A
(es)
*
|
2017-03-30 |
2019-11-18 |
Merck Patent Gmbh |
Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
CN110785431B
(zh)
*
|
2017-05-04 |
2024-05-07 |
阿塞勒隆制药公司 |
TGF-β受体II型融合蛋白及其用途
|
|
US11440963B2
(en)
|
2017-05-09 |
2022-09-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
|
|
UA128306C2
(uk)
*
|
2017-05-12 |
2024-06-05 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
ЗЛИТІ ПРОТЕЇНИ, ЯКІ МІСТЯТЬ РЕЦЕПТОР TGF-<font face="Symbol">b</font>, І ЇХ ФАРМАЦЕВТИЧНЕ ЗАСТОСУВАННЯ
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
AU2018338612A1
(en)
|
2017-09-27 |
2020-05-07 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
WO2019090263A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
US20200377571A1
(en)
*
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
BR112020017382A2
(pt)
|
2018-03-09 |
2021-01-26 |
Agenus Inc. |
anticorpos anti-cd73 e métodos de uso dos mesmos
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019175243A1
(en)
|
2018-03-14 |
2019-09-19 |
Merck Patent Gmbh |
Compounds and uses thereof to treat tumors in a subject
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US11065317B2
(en)
|
2018-04-26 |
2021-07-20 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
AU2019262139A1
(en)
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Multispecific binders of TGFβ-superfamily ligands and uses thereof
|
|
CA3099325A1
(en)
*
|
2018-05-03 |
2019-11-07 |
Acceleron Pharma Inc. |
Novel binders of tgf.beta.-superfamily ligands and uses thereof
|
|
BR112020022145A2
(pt)
|
2018-05-04 |
2021-01-26 |
Merck Patent Gmbh |
inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
|
|
CN112118858A
(zh)
*
|
2018-05-15 |
2020-12-22 |
默克专利有限公司 |
用于未经治疗对象中癌症治疗的靶向tgf-β抑制的给药方案
|
|
AU2019270178A1
(en)
|
2018-05-17 |
2021-01-07 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
MX2020013535A
(es)
*
|
2018-06-13 |
2021-02-26 |
Merck Patent Gmbh |
Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.
|
|
CN111867630B
(zh)
|
2018-06-17 |
2023-10-13 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
KR20210022680A
(ko)
*
|
2018-06-22 |
2021-03-03 |
메르크 파텐트 게엠베하 |
담도암의 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘
|
|
EP3813864A4
(en)
|
2018-06-29 |
2022-07-20 |
Gensun Biopharma Inc. |
Antitumor antagonists
|
|
JP2021529777A
(ja)
*
|
2018-07-02 |
2021-11-04 |
メルク パテント ゲーエムベーハー |
進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AU2019301070B2
(en)
|
2018-07-09 |
2025-09-11 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
SG11202101663WA
(en)
*
|
2018-08-22 |
2021-03-30 |
Merck Patent Gmbh |
Treatment of triple negative breast cancer with targeted tgf-b inhibition
|
|
WO2020069372A1
(en)
|
2018-09-27 |
2020-04-02 |
Elstar Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
|
JP2022505925A
(ja)
|
2018-11-01 |
2022-01-14 |
メルク パテント ゲーエムベーハー |
抗ｔｉｍ－３抗体
|
|
AU2019372436A1
(en)
*
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
KR102881644B1
(ko)
|
2018-11-09 |
2025-11-06 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
TGF-β 수용체 융합 단백질 약학적 조성물 및 이의 용도
|
|
JP7571021B2
(ja)
*
|
2018-12-06 |
2024-10-22 |
グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド |
腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法
|
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
US20220226491A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting PD-L1
|
|
CN114206926B
(zh)
|
2019-06-10 |
2022-06-17 |
山东博安生物技术股份有限公司 |
抗PDL1和TGFβ的双功能融合蛋白及其用途
|
|
CA3142887A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CN110218260A
(zh)
*
|
2019-06-24 |
2019-09-10 |
王跃驹 |
植物作为宿主在表达m7842中的应用
|
|
WO2020263312A1
(en)
*
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN112239507A
(zh)
|
2019-07-17 |
2021-01-19 |
鸿运华宁（杭州）生物医药有限公司 |
ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
|
|
EP4013507A1
(en)
*
|
2019-08-15 |
2022-06-22 |
NantBio, Inc. |
Tgf-beta trap
|
|
CN114072428B
(zh)
|
2019-08-30 |
2024-02-13 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
|
AU2020335928A1
(en)
|
2019-08-30 |
2022-02-17 |
Agenus Inc. |
Anti-CD96 antibodies and methods of use thereof
|
|
WO2021046112A1
(en)
|
2019-09-03 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
EP4025255A1
(en)
|
2019-09-04 |
2022-07-13 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
CN112442132A
(zh)
*
|
2019-09-05 |
2021-03-05 |
复旦大学 |
靶向肿瘤的重组双功能融合蛋白及其应用
|
|
CN112480253B
(zh)
|
2019-09-12 |
2022-09-20 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
WO2021063352A1
(zh)
*
|
2019-09-30 |
2021-04-08 |
和铂医药(上海)有限责任公司 |
一种抗pd-l1抗原结合蛋白及其应用
|
|
WO2021067242A1
(en)
|
2019-09-30 |
2021-04-08 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
EP4048704A4
(en)
*
|
2019-10-21 |
2023-11-22 |
Nanjing Leads Biolabs Co., Ltd. |
RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
|
|
TWI857167B
(zh)
|
2019-10-25 |
2024-10-01 |
美商博特生物治療公司 |
噻吩并氮呯免疫結合物及其用途
|
|
CA3154413A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Yan Lan |
Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
|
|
IL292758A
(en)
*
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
|
TW202128763A
(zh)
*
|
2019-11-12 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
|
|
TWI772984B
(zh)
*
|
2019-11-27 |
2022-08-01 |
大陸商上海岸邁生物科技有限公司 |
TGFβ/PD-L1雙特異性結合蛋白
|
|
CA3158047A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Yunying CHEN |
Bi-functional antibody against pd-l1 and tgf?
|
|
EP4076388A1
(en)
|
2019-12-20 |
2022-10-26 |
Ares Trading S.A. |
Igg:tgfbetarii fusion protein composition
|
|
EP3838260A1
(en)
|
2019-12-20 |
2021-06-23 |
Ares Trading S.A. |
Igg:tgf rii fusion protein composition
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
EP4087866A1
(en)
*
|
2020-01-09 |
2022-11-16 |
F. Hoffmann-La Roche AG |
New 4-1bbl trimer-containing antigen binding molecules
|
|
MX2022008925A
(es)
|
2020-01-21 |
2022-10-18 |
Bolt Biotherapeutics Inc |
Anticuerpos anti-pd-l1.
|
|
US20230069055A1
(en)
|
2020-01-21 |
2023-03-02 |
Bolt Biotherapeutics, Inc |
Anti-pd-l1 antibodies
|
|
US20230093512A1
(en)
*
|
2020-02-18 |
2023-03-23 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion proteins and uses thereof
|
|
EP4093779A4
(en)
*
|
2020-02-25 |
2024-03-06 |
Wuxi Biologics Ireland Limited |
BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
|
|
WO2021185337A1
(zh)
|
2020-03-20 |
2021-09-23 |
荣昌生物制药(烟台)股份有限公司 |
一种双特异性融合蛋白及其应用
|
|
AU2021256925A1
(en)
*
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
KR20230002261A
(ko)
|
2020-04-28 |
2023-01-05 |
더 락커펠러 유니버시티 |
항-sars-cov-2 중화 항체 및 이의 사용 방법
|
|
AU2021263650A1
(en)
*
|
2020-04-29 |
2023-01-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Bifunctional protein against PD-1 and TGF-beta
|
|
CA3175576A1
(en)
|
2020-05-01 |
2021-11-04 |
Shelley Erin ACKERMAN |
Anti-dectin-2 antibodies
|
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
US20230357793A1
(en)
*
|
2020-06-26 |
2023-11-09 |
Sorrento Therapeutics, Inc. |
Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
|
|
IL299764A
(en)
|
2020-07-10 |
2023-03-01 |
Precigen Inc |
Fusion constructs and methods for using them
|
|
CN113968903A
(zh)
*
|
2020-07-24 |
2022-01-25 |
迈威(上海)生物科技股份有限公司 |
TGF-β RII突变体及其融合蛋白
|
|
US20230287125A1
(en)
*
|
2020-07-28 |
2023-09-14 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting pd-l1 and tgf-beta
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
TW202214287A
(zh)
*
|
2020-08-24 |
2022-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2022042715A1
(zh)
*
|
2020-08-31 |
2022-03-03 |
杭州九源基因工程有限公司 |
靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
WO2022057821A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co. , Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
CN116390940A
(zh)
*
|
2020-09-23 |
2023-07-04 |
海正生物制药有限公司 |
Tgfbr2-ecd突变体及包含其的融合蛋白与应用
|
|
CN116323657B
(zh)
*
|
2020-09-24 |
2023-12-08 |
上海齐鲁制药研究中心有限公司 |
同时靶向PD-L1和TGFβ的双功能分子及其医药用途
|
|
CN114349867B
(zh)
*
|
2020-10-14 |
2024-05-28 |
广东菲鹏制药股份有限公司 |
融合蛋白及其应用
|
|
WO2022090527A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
WO2022090529A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CN114573701A
(zh)
*
|
2020-12-02 |
2022-06-03 |
上海华奥泰生物药业股份有限公司 |
抗PD-L1/TGF-β双功能抗体及其用途
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
EP4259209A1
(en)
|
2020-12-11 |
2023-10-18 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 immunoconjugates, and uses thereof
|
|
CA3200051A1
(en)
|
2020-12-11 |
2022-06-16 |
Shelley Erin ACKERMAN |
Anti-cea immunoconjugates, and uses thereof
|
|
WO2022174451A1
(zh)
|
2021-02-22 |
2022-08-25 |
浙江道尔生物科技有限公司 |
一种具有抗癌活性的多结构域融合蛋白
|
|
CN116917273A
(zh)
|
2021-03-02 |
2023-10-20 |
葛兰素史克知识产权发展有限公司 |
作为dnmt1抑制剂的经取代的吡啶
|
|
IL306114A
(en)
|
2021-03-26 |
2023-11-01 |
Bolt Biotherapeutics Inc |
2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof
|
|
JP2024511088A
(ja)
|
2021-03-26 |
2024-03-12 |
ボルト バイオセラピューティクス、インコーポレーテッド |
２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用
|
|
WO2022233718A2
(en)
|
2021-05-03 |
2022-11-10 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
CN114773485B
(zh)
*
|
2021-05-11 |
2024-05-17 |
江苏先声药业有限公司 |
抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
|
|
US20240226319A1
(en)
|
2021-05-25 |
2024-07-11 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
CA3220380A1
(en)
|
2021-06-07 |
2022-12-15 |
Rinat ZAYNAGETDINOV |
Combination treatment of cancer
|
|
CA3230292A1
(en)
*
|
2021-08-27 |
2023-03-02 |
Theranotics Co., Ltd. |
Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof
|
|
AU2023210700A1
(en)
|
2022-01-28 |
2024-08-15 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
CN114990129B
(zh)
*
|
2022-05-11 |
2023-02-03 |
北京贝来生物科技有限公司 |
表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
|
|
EP4527857A1
(en)
|
2022-05-17 |
2025-03-26 |
Suzhou Transcenta Therapeutics Co., Ltd. |
Bifunctional protein, and preparation thereof and use thereof
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
JP2026506037A
(ja)
|
2023-02-14 |
2026-02-20 |
ボルト バイオセラピューティクス、インコーポレーテッド |
アザベンズアゼピンイムノコンジュゲート及びその使用
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024216089A1
(en)
|
2023-04-13 |
2024-10-17 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibody combination therapy
|
|
AU2024372189A1
(en)
*
|
2023-10-31 |
2026-03-05 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
WO2025110822A1
(ko)
*
|
2023-11-24 |
2025-05-30 |
주식회사 메드팩토 |
피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
|
|
WO2025140212A1
(en)
*
|
2023-12-26 |
2025-07-03 |
Laekna Therapeutics Shanghai Co., Ltd. |
Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
|
|
EP4653010A1
(en)
|
2024-05-14 |
2025-11-26 |
35Pharma Inc. |
Activin receptor type iib traps for use in improving body composition
|
|
WO2026050213A1
(en)
|
2024-08-27 |
2026-03-05 |
Usbolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|